NDAINTRAVENOUSPOWDER
Approved
May 2002
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
5/8 — Partial
VFEND (voriconazole) by Pfizer is cytochrome p450 3a4 inhibitors [moa]. Approved for aspergillosis, candidiasis, invasive candidiasis and 3 more indications. First approved in 2002.
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VFEND (voriconazole) is an intravenous azole antifungal that inhibits Cytochrome P450 3A4, blocking fungal ergosterol synthesis. It treats serious invasive fungal infections including aspergillosis, candidiasis, cryptococcosis, and blastomycosis, primarily in immunocompromised patients. The drug has broad-spectrum coverage and is considered a cornerstone therapy for invasive fungal infections in hospital settings.
$0.01BPart D
LOE ApproachingDeclining
LOE-approaching lifecycle signals declining brand investment and consolidation of internal teams; roles shifting toward generic transition support and specialty channel management.
Mechanism of Action
Cytochrome P450 3A4 Inhibitors
Pharmacologic Class:
Azole Antifungal
Indications (6)
Worked on VFEND at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.